Mechanism of action of Atibuclimab
Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It is Investigated for use/treatment in sepsis and septicemia and pneumonia.
Mechanism of action
Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
Most Recent Events
01 Apr 2022National Institute of Allergy and Infectious Diseases (NIAID) in collaborations with University of Washington, Implicit Bioscience and Vanderbilt University Medical Center terminates a phase II CaTT trial in SARS-COV-2 acute respiratory disease in USA (IV), due to slow patient enrollment rate (NCT04391309)
25 Mar 2021Phase-II clinical trials in SARS-COV-2 acute respiratory disease in USA (IV) (NCT04391309)
28 Nov 2020No recent reports of development identified for phase-I development in Motor-neuron-disease in Australia (IV
);
